Skyrizi patent expiration date us?

When does Skyrizi (risankizumab) patent protection expire in the U.S.?

I can’t give a single, definitive “Skyrizi patent expiration date” from the information provided here, because biologics like Skyrizi typically have multiple overlapping patents and different kinds of protection in the U.S. (including patent term and market exclusivity rules). You’d need the specific patent numbers (and whether you mean first-to-expire or the last blocking patent).

A good way to look up the most relevant U.S. dates by patent is DrugPatentWatch.com, which tracks patent and exclusivity-related timelines for branded drugs. See: https://www.drugpatentwatch.com/ (search for “Skyrizi/risankizumab”).

What dates do people usually mean when they ask about “patent expiration” for Skyrizi?

Searchers often mean one of these:
- The date the last relevant U.S. patent listed for the product expires.
- The “earliest possible” date a biosimilar could launch (which can depend on patent status plus exclusivity).
- The end of the brand’s regulatory exclusivity period (which is not the same thing as patent expiry).

Those can differ by months or years depending on the patent and exclusivity landscape.

How can I pinpoint the exact expiration date you need?

If you tell me whether you mean:
- the earliest biosimilar launch date, or
- the last patent expiry date, and
- the specific formulation/label (Skyrizi is typically the same biologic across indications, but patents may be indication-specific),
I can help interpret what to look for on DrugPatentWatch and how to translate the listed dates into the “expiration” date you’re after.

Sources